What is Claimed:

1. Use of an antibody or fragment thereof for the preparation of a medicament for the treatment of nail or scalp psoriasis, wherein the antibody or fragment thereof specifically binds to IL-17receptor RA (IL-17RA) and has an antagonistic activity.

2. A composition for use in the treatment of nail or scalp psoriasis, wherein the composition comprises an antibody or fragment thereof that specifically binds to IL-17receptor RA (IL-17RA) and has an antagonistic activity.

3. The use of claim 1, or the composition for use of claim 2, wherein the antibody or fragment thereof is selected from:
a. an antibody, comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:8;
b. an antibody comprising the full length light chain amino acid sequence of SEQ ID NO: 9 and a full length heavy chain amino acid sequence of SEQ ID NO: 10 and
c. an antibody, comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:1, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:2, a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:3, a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:4, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:6.

4. The use of claim 1 or 3, or the composition for use of claim 2 or 3, wherein the antibody or fragment thereof inhibits binding of IL-17A to said IL-17RA.

5. The use of any one of claims 1, 3 and 4, or the composition for use of any one of claims 2-4, wherein the medicament or composition is to be administered to a patient suffering from psoriasis.

6. The use of any one of claims 1, 3-5, or the composition for use of any one of claims 2-5, wherein the medicament or composition is to be administered to a patient suffering from plaque psoriasis, pustular psoriasis or psoriatic erythroderma.

7. The use of claim 5 or 6, or the composition for use of claim 5 or 6, wherein the patient has a Nail Psoriasis Severity Index (NAPSI) score of at least 6 or a modified NAPSI score of at least 2 or 3 on one or more nails.

8. The use of any one of claims 5-7, or the composition for use of any one of claims 5-7, wherein the patient has a Psoriasis Scalp Severity Index (PSSI) score of at least 15.

9. The use of any one of claims 1 and 3-8, or the composition for use of any one of claims 2-8, where the patient has a Scalp Surface Area (SSA) score of at least 30%.

10. The use of any one of claims 1 and 3-9, or the composition for use of any one of claims 2-9, wherein the medicament or composition comprises a dose of antibody that is 70 mg, 140mg, 210 mg or 280 mg.

11. The use of any one of claims 1 and 3-10, or the composition for use of any one of claims 2-10, wherein the medicament or composition is to be administered to a patient having 10% or greater body surface area affected by moderate to severe psoriasis and additionally having nail or scalp psoriasis.

12. The use of any one of claims 1 and 3-11, or the composition for use of any one of claims 2-11, wherein the medicament or composition is to be administered with a second treatment.

13. The use of claim 12, or the composition for use of claim 12, wherein said second treatment is to be administered prior to, concurrent with, or subsequent to administration of said medicament or composition comprising said antibody.

14. The use of claim 12 or 13, or the composition for use of claim 12 or 13, wherein the second treatment is a topical treatment.

15. The use of claim 14, or the composition for use of claim 14, wherein the topical treatment is selected from the group consisting fluorouracil, dithranol, tazarotene, cyclosporine, calcineneurin inhibitors, triamcinolone, fluocinonide, topical steroids, vitamin D_3, vitamin D_3 analogs, betamethasone dipropionate, betamethasone valerate, calcipotriol, clobetasol, XAMIOL, DAIVOBET, coal tar, urea, corticosteroids, retinoids, anthralin, topical methatrexate, keratolytics, salicylic acid, tofacitinab, apremilast, topical JAK inhibitors or a combination thereof.

16. The use of any one of claims 12-15, or the composition for use of any one of claims 12-15, wherein the second treatment is selected from the group consisting of retinoids, acitretin cyclosporine, methotrexate, apremilast, tofacitinib, oral JAK inhibitors, oral PI3 kinase inhibitors, oral MAP kinase inhibitors, Fumaderm, fumarates, dimethyl fumarate, sulfasalazine, leflunomide, calcineurin inhibitors, azathioprine, thioguanine, hydroxyurea, hydroxychloroquine, sulfasalazine, antifungals or a combination thereof.

17. The use of any one of claims 12-16, or the composition for use of any one of claims 12-16, wherein the second treatment is an antibody or chimeric protein specific for TNF, IL-17, IL-12/23 or IL-23.

18. The use of claim 17, or the composition for use of claim 17, wherein the antibody or chimeric protein is infliximab, adalimumab, etanercept, alefacept, ustekinumab, secukinumab, ixekizumab, guselkumab, antifungals or a combination thereof.

19. The use of any one of claims 12-18, or the composition for use of any one of claims 12-18, wherein the second treatment is selected from the group consisting of is triamcinolone acetonide photochemotherapy, laser therapy, Excimer laser, oral/topical psorallen with UVA (PUVA), pulsed dye laser, radiation therapy, superficial radiotherapy, electron beam therapy, Grenz ray therapy, ermatome shaving, aloe vera extract, narrow band UV therapy UV therapy or a combination thereof.

20. The use of any one of claims 1 and 3-19, or the composition for use of any one of claims 2-19, wherein said antibody is selected from the group consisting of:
a. a humanized antibody;

b. a chimeric antibody;

c. a monoclonal antibody;

d. an antigen-binding antibody fragment;

e. a single chain antibody;

f. a diabody;

g. a triabody;

h. a tetrabody;

i. a Fab fragment;

j. a F(ab')2 fragment;

k. an IgD antibody;

l. an IgE antibody;

m. an IgM antibody;

n. an IgG1 antibody;

o. an IgG2 antibody;

p. an IgG3 antibody; and

q.an IgG4 antibody.

21. The use of any one of claims 1 and 3-20, or the composition for use of any one of claims 2-20, wherein said medicament or composition further comprises a pharmaceutically acceptable diluent.

22. The use of any one of claims 1 and 3-21, or the composition for use of any one of claims 2-21, wherein said medicament or composition comprises an aqueous solution of a glutamic acid buffer comprising a) said glutamic acid buffer comprises a glutamic acid concentration of 5-30 mM.+-.0.2 mM; b) said glutamic acid buffer comprises a pH of 4.5-5.2.+-.0.2; c) said formulation further comprises 2-4% proline (w/v) and 0.005-0.02% (w/v) polysorbate 20 and d) the antibody or fragment thereof at a concentration of 100 to 150 mg/ml.

23. The use of claim 22, or the composition for use of claim 22, wherein the medicament or composition has an osmolarity of 275 to 325 osm.

24. The use of claim 22 or 23, or the composition for use of claim 22 or 23, wherein the medicament or composition has a viscosity of 5 to 7 cP at 25°C.

25. The use of any one of claims 1 and 3-24, or the composition for use of any one of claims 2-24, wherein said antibody is a human IgG2 monoclonal antibody.